Clinical Trials Browser

OTHER × spartalizumab × Gynecologic × Clear all

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT05824468 2026-03-10

Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer

Phase 2 Active not recruiting

Uterine Cervical Neoplasms

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03757858 2024-02-07

Hyperthermia Combined With Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases

Phase 1/2 Completed

Neoplasm Metastasis, Neoplasms, Pelvic Neoplasms

NCT05511623 2023-09-11

Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer

Phase 2 Recruiting

Uterine Cervical Neoplasms

NCT04368273 2020-04-29

CCRT+PD-1

Phase 1/2 Unknown

Uterine Cervical Neoplasms